| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Lactotransferrin;Lactoferrin;3.4.21.-;Growth-inhibiting protein 12;Talalactoferrin;Lactoferricin-H;Lfcin-H;Kaliocin-1;Lactoferroxin-A;Lactoferroxin-B;Lactoferroxin-C;LTF;GIG12, LF; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human Lactoferrin |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-LTF antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 22L00; isotype IgG; reactivity: Human. Reported application contexts include WB, ICC, IF, IP (as provided in the source record). Boster Bio Anti-Lactoferrin Rabbit Monoclonal Antibody catalog # M00633-2. Tested in WB, ICC/IF, IP applications. This antibody reacts with Human.
Key elements and design rationale
- Target: LTF (Lactotransferrin).
- Antibody format: Monoclonal; clone 22L00; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
LTF (protein: T-cell surface glycoprotein CD4) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Transferrins are iron binding transport proteins which can bind two Fe (3+) ions in association with the binding of an anion, usually bicarbonate. Reported cellular localization context: Isoform 1: Secreted. Cytoplasmic granule. Secreted into most exocrine fluids by various endothelial cells. Stored in the secondary granules of neutrophils. Tissue expression notes (as provided): High levels are found in saliva and tears, intermediate levels in serum and plasma, and low levels in urine. In kidney, detected in the distal collecting tubules in the medulla but not in the cortical region or in blood vessels. Detected in peripheral blood neutrophils (at protein level). Isoform 1 and isoform DeltaLf are expressed in breast, prostate, spleen, pancreas, kidney, small intestine, lung, skeletal muscle, uterus, thymus and fetal liver. Isoform 1 is expressed in brain, testis and peripheral blood leukocytes; isoform DeltaLf is barely detectable in these tissues. Isoform DeltaLf is expressed in placenta, liver and ovary; isoform 1 is barely detectable in these tissues. In kidney, isoform 1 is expressed at high levels in the collecting tubules of the medulla but at very low levels in the cortex. .
Research relevance and current trends
- Research context keywords from the source record include: Apoptosis,Cancer,Cardiovascular,Cell Death,Invasion/Microenvironment,Serum Proteins.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
- Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
- Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.
Workflow ideas (metafield): Validate LTF antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect LTF expression by Western blot in cell or tissue lysates, Localize LTF by immunofluorescence/immunocytochemistry in cultured cells, Enrich LTF by immunoprecipitation from lysates for downstream analysis
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 85 kDa; calculated MW: 78182 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 85 kDa
- Cellular localization (provided): Isoform 1: Secreted. Cytoplasmic granule. Secreted into most exocrine fluids by various endothelial cells. Stored in the secondary granules of neutrophils.
- Tissue details (provided): High levels are found in saliva and tears, intermediate levels in serum and plasma, and low levels in urine. In kidney, detected in the distal collecting tubules in the medulla but not in the cortical region or in blood vessels. Detected in peripheral blood neutrophils (at protein level). Isoform 1 and isoform DeltaLf are expressed in breast, prostate, spleen, pancreas, kidney, small intestine, lung, skeletal muscle, uterus, thymus and fetal liver. Isoform 1 is expressed in brain, testis and peripheral blood leukocytes; isoform DeltaLf is barely detectable in these tissues. Isoform DeltaLf is expressed in placenta, liver and ovary; isoform 1 is barely detectable in these tissues. In kidney, isoform 1 is expressed at high levels in the collecting tubules of the medulla but at very low levels in the cortex. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.